In the US, approximately 500,000 individuals are hospitalized yearly for traumatic brain injury (TBI), and posttraumatic epilepsy (PTE) is a common sequela of TBI. Improved treatment strategies for PTE are critically needed, as patients with the disorder are often resistant to antiepileptic medications and are poor candidates for definitive resection. Vagus nerve stimulation (VNS) is an adjunctive treatment for medically refractory epilepsy that results in a ≥50% reduction in seizure frequency in approximately 50% of patients after 1 year of therapy. The role of VNS in PTE has been poorly studied. The aim of this study was to determine whether patients with PTE attain more favorable seizure outcomes than individuals with nontraumatic epilepsy etiologies.

Methods. Using a case-control study design, the authors retrospectively compared seizure outcomes after VNS therapy in patients with PTE versus those with nontraumatic epilepsy (non-PTE) who were part of a large prospectively collected patient registry.

Results. After VNS therapy, patients with PTE demonstrated a greater reduction in seizure frequency (50% fewer seizures at the 3-month follow-up; 73% fewer seizures at 24 months) than patients with non-PTE (46% fewer seizures at 3 months; 57% fewer seizures at 24 months). Overall, patients with PTE had a 78% rate of clinical response to VNS therapy at 24 months (that is, ≥50% reduction in seizure frequency) as compared with a 61% response rate among patients with non-PTE (OR 1.32, 95% CI 1.07–1.61), leading to improved outcomes according to the Engel classification (p < 0.0001, Cochran-Mantel-Haenszel statistic).

Conclusions. Vagus nerve stimulation should be considered in patients with medically refractory PTE who are not good candidates for resection. A controlled prospective trial is necessary to further examine seizure outcomes as well as neuropsychological outcomes after VNS therapy in patients with intractable PTE.

Key Words • posttraumatic epilepsy • seizure • epilepsy • traumatic brain injury • vagus nerve stimulation

Abbreviations used in this paper: AED = antiepileptic drug; PTE = posttraumatic epilepsy; TBI = traumatic brain injury; VNS = vagus nerve stimulation.
Vagus nerve stimulation for posttraumatic epilepsy

The potential benefits of VNS therapy in the PTE population have been poorly studied. However, 2 recent retrospective case series have revealed dramatic reductions in seizure frequency among patients with PTE (68%–85%) after VNS therapy, suggesting that patients with PTE may respond more favorably to treatment than those with nontraumatic epileptic disorders.1,2,24 Furthermore, a recent meta-analysis has indicated that patients with PTE may achieve greater benefits from VNS than individuals with other epilepsy etiologies, but these conclusions were limited by the small number of patients in the study.14

Here, we examined a large, prospectively collected patient registry and analyzed seizure outcomes after VNS for drug-resistant epilepsy to determine whether patients with PTE attain more favorable seizure outcomes than individuals with nontraumatic epilepsy etiologies.

Methods

Patient Outcome Registry Data Collection

All data were obtained from the VNS Therapy Patient Outcome Registry maintained by the manufacturer of the VNS therapy system (Cyberonics, Inc.). This database was established in 1999, after FDA approval of VNS for the treatment of epilepsy in 1997, to systematically monitor patient outcomes. Data at preoperative baselines and various intervals during therapy were prospectively and voluntarily provided by 1285 prescribing physicians from 978 centers (911 in the US and Canada and 67 international centers). Neurologists or their designated staff completed standard case report forms based on a patient’s medical history or current visit and voluntarily sent these forms to Cyberonics for data entry. At baseline, a patient’s history and implant form was submitted, containing information on patient demographics, epilepsy etiology and syndrome, historical seizure types and frequencies, quality of life, physician global assessment, and current AEDs. At each follow-up visit, information was collected on seizure types, seizure frequency (overall and by seizure type), a customized quality of life measure, and current AEDs. Active data collection ceased in 2003. Previous investigators have authenticated the integrity of the system for collecting and processing registry data using an independent auditing agency.3 The database was queried in September 2011, and all seizure outcomes reported at 3, 6, 12, and 24 months after VNS device implantation were extracted and compared with preoperative baselines using the Engel classification scheme.12 The overall percentage decrease in seizure frequency versus baseline and response rates to VNS therapy were also calculated at each follow-up visit using the seizure rates reported by the treating neurologist at each visit. Patients with a ≥ 50% decrease in seizure frequency after VNS versus preoperative baseline levels were designated “responders,” whereas those without a ≥ 50% decrease in seizure frequency were labeled “nonresponders.” Other data extracted for all patients included sex, race, age at diagnosis, age at stimulator implantation, and preoperative duration of epilepsy.

To determine whether seizure outcomes after VNS therapy differed between patients with or without PTE, epilepsy etiology was examined. Epilepsy etiology was reported by the prescribing physician at the time of device implantation for many patients and was not independently verified. Based on this information, patients were classified into one of the following groups: 1) epilepsy resulting from trauma, or PTE (for example, “posttraumatic,” “status post–head injury,” “status postcontusion,” or “gunshot injury to head”); 2) epilepsy unrelated to trauma, or non-PTE (for example, “mesial temporal sclerosis,” “tumor,” “infection,” or “stroke”); or 3) ambiguous/indeterminate (for example, “possible posttraumatic,” “fall,” “accident,” or “brain hemorrhage”). Patients were excluded from analysis if an ambiguous/indeterminate epilepsy etiology was present, if the etiology was unknown or unreported, if both traumatic and nontraumatic etiologies were reported, if a history of childbirth-related injury was reported (given inability to disaggregate between traumatic, anoxic, or other possible epilepsy etiologies), or if no data from postoperative follow-up evaluations were available. Collected data did not specify the location, severity, or penetrating status of the TBI since the registry was not designed for PTE in particular. Furthermore, the registry is further limited in that there is no information on trauma origin for patients with PTE (that is, military or civilian).

Statistical Analysis

Patient sex, race, age at diagnosis, age at device implantation, preoperative duration of epilepsy, baseline seizure frequency, baseline seizure type, and number of AEDs were compared for PTE versus non-PTE patients using the Student t-test for continuous variables and the chi-square test for categorical variables. Initial analysis using all available data showed a statistically significant difference in response for PTE versus non-PTE patients, but the 2 groups also had statistical differences in sex and age, suggesting possible confounding by these variables. Thus, a case-control study design was used to control for the potentially influential covariates of sex, age at diagnosis, and age at implantation to assess the association between etiology (PTE versus non-PTE) and percentage of seizure decrease, responder status, or Engel outcome class. To determine if etiology was an independent variable affecting patient outcome, a case-control design was chosen over a multivariate analysis approach, as all of the data for case-control matching were readily available, and the result was a more direct comparison of the outcomes for the 2 groups. During the case-control record selection, for each PTE patient record, 2 non-PTE patient records were matched according to sex, follow-up time, age at implantation, and age at diagnosis. This selection process was done without any consideration for the response variables. Unmatched patient data were removed from analysis. The Wilcoxon rank-sum test and 2-proportion z-test were used to compare the median percentage decrease in seizure frequency and the responder rates, respectively, between PTE and non-PTE patients at each follow-up time point. The Cochran-Mantel-Haenszel statistic for
row mean scores was used to test whether there was a relationship between etiology type (PTE or non-PTE) and Engel class, controlling for the 4 follow-up time points in all instances. An odds ratio with a 95% confidence interval was calculated to measure the overall likelihood of attaining a clinical response (≥ 50% reduced seizure frequency) between PTE and non-PTE patients by utilizing the Breslow-Day test for homogeneity of the odds ratios at the different follow-up times. The level of significance was set at 0.05 for all analyses. Statistical analysis was performed using SAS version 9.2 (SAS Institute, Inc.).

Results

Data from patients with PTE or non-PTE etiologies were extracted from 7383 individuals in the VNS patient registry. Patients with unknown, ambiguous, or multiple etiologies, as well as those without postoperative follow-up, were excluded from analysis (Fig. 1). Overall, data from 637 postoperative visits in 317 PTE patients were compared with 3666 visits in 1763 non-PTE patients.

Initial review of the raw outcome data revealed a progressive decrease in seizure frequency and an increase in the responder rate in both PTE and non-PTE patients over time after VNS therapy. Furthermore, observed trends suggested that, compared with non-PTE patients, the PTE population demonstrated a greater overall decrease in seizure frequency (Fig. 2A), a greater increase in the response rate (Fig. 2B), and more favorable Engel outcomes over time (Fig. 2C–D). However, differences in baseline demographics for the PTE and non-PTE patient pools made unadjusted statistical comparisons inappropriate. As summarized in Table 1, at 24 months after implantation, PTE and non-PTE patient groups exhibited significant differences in sex, age at implant, and age at diagnosis. Thus, a case-control study design was used in which 2 non-PTE patient records were matched to each PTE patient record according to baseline patient demographics without any consideration for the response variables. Repeat analysis of demographic data using the case-control study design revealed no significant differences in baseline characteristics between PTE and non-PTE patients.

Utilizing the case-control study design, a larger progressive reduction in seizure frequency was observed in PTE patients after VNS therapy (50% fewer seizures at 3 months; 73% fewer seizures at 24 months) as compared with non-PTE patients after VNS therapy (46% fewer seizures at 3 months; 57% fewer seizures at 24 months; Fig. 3A). This difference was statistically significant at 6 and 12 months postoperatively (p = 0.03 and p < 0.01, respectively) but did not reach statistical significance at 3 or 24 months (p = 0.14 and p = 0.15, respectively). Moreover, the rate of clinical response at 24 months was significantly higher among PTE patients (78% responders) versus non-PTE patients (61% responders; p = 0.02; Fig. 3B), leading to more favorable Engel outcomes in the PTE patient population at the last follow-up (Fig. 3C–D). Importantly, the reduction in seizure frequency was greater and the response rate higher in PTE patients versus non-PTE patients at every available follow-up interval analyzed.

Overall, after controlling for the 4 postoperative follow-up durations, there was a strong statistical rela-
Vagus nerve stimulation for posttraumatic epilepsy

TABLE 1: Summary of demographic data for PTE versus non-PTE patients*

<table>
<thead>
<tr>
<th>Variable</th>
<th>FU Duration (mos)</th>
<th>PTE Patients</th>
<th>Non-PTE Patients</th>
<th>p Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>raw patient data</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sex (%M)</td>
<td>3</td>
<td>57</td>
<td>54</td>
<td>0.32</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>63</td>
<td>50</td>
<td>0.04‡</td>
</tr>
<tr>
<td>race</td>
<td>3</td>
<td>86% white; 5% black; 5% Hispanic; 4% other</td>
<td>83% white; 5% black; 7% Hispanic; 5% other</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>90% white; 3% black; 1% Hispanic; 6% other</td>
<td>85% white; 3% black; 4% Hispanic; 7% other</td>
<td>0.59</td>
</tr>
<tr>
<td>mean age at implant (yrs)</td>
<td>3</td>
<td>37.9 ± 12.8</td>
<td>24.9 ± 15.2</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>37.2 ± 13.1</td>
<td>27.5 ± 14.1</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>mean age at diagnosis (yrs)</td>
<td>3</td>
<td>14.5 ± 14.5</td>
<td>6.8 ± 10.2</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>13.5 ± 10.2</td>
<td>6.8 ± 10.0</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>mean preop duration of epilepsy (yrs)</td>
<td>3</td>
<td>23.2 ± 14.1</td>
<td>17.7 ± 12.6</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>23.7 ± 13.0</td>
<td>20.7 ± 12.7</td>
<td>0.08</td>
</tr>
<tr>
<td>mean baseline seizure frequency per mo†</td>
<td>3</td>
<td>12.2 ± 9.8</td>
<td>30.0 ± 26.0</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>27.0 ± 17.0</td>
<td>25.0 ± 20.5</td>
<td>0.71</td>
</tr>
<tr>
<td>case-control data</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sex (%M)</td>
<td>3</td>
<td>55</td>
<td>55</td>
<td>0.99</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>56</td>
<td>56</td>
<td>0.99</td>
</tr>
<tr>
<td>race</td>
<td>3</td>
<td>87% white; 5% black; 4% Hispanic; 4% other</td>
<td>84% white; 5% black; 6% Hispanic; 5% other</td>
<td>0.62</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>88% white; 3% black; 2% Hispanic; 7% other</td>
<td>85% white; 4% black; 6% Hispanic; 6% other</td>
<td>0.73</td>
</tr>
<tr>
<td>mean age at implant (yrs)</td>
<td>3</td>
<td>37.0 ± 12.2</td>
<td>35.3 ± 11.7</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>34.2 ± 12.1</td>
<td>32.8 ± 10.6</td>
<td>0.45</td>
</tr>
<tr>
<td>mean age at diagnosis (yrs)</td>
<td>3</td>
<td>13.9 ± 11.2</td>
<td>13.3 ± 11.3</td>
<td>0.51</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>11.5 ± 9.0</td>
<td>10.8 ± 9.7</td>
<td>0.65</td>
</tr>
<tr>
<td>mean preop duration of epilepsy (yrs)</td>
<td>3</td>
<td>22.9 ± 14.0</td>
<td>21.8 ± 11.2</td>
<td>0.28</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>22.5 ± 13.1</td>
<td>21.7 ± 11.2</td>
<td>0.68</td>
</tr>
<tr>
<td>median baseline seizure frequency per mo§</td>
<td>3</td>
<td>14.0 ± 11.0</td>
<td>15.0 ± 11.0</td>
<td>0.67</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>27.0 ± 17.0</td>
<td>14.0 ± 11.0</td>
<td>0.21</td>
</tr>
</tbody>
</table>

* Values represent the means ± standard deviations unless indicated otherwise. For raw data, the number of patients with relevant data = 257 (PTE) and 1468 (non-PTE) at 3 months and 71 (PTE) and 389 (non-PTE) at 24 months. For case-control data, the number of patients with relevant data = 239 (PTE) and 478 (non-PTE) at 3 months and 59 (PTE) and 118 (non-PTE) at 24 months. Abbreviation: FU = follow-up.
† Reflects the Student t-test to compare the means of continuous variables, unless data were nonnormal, in which case the Wilcoxon rank-sum test was used to compare medians (that is, baseline seizure frequency); the chi-square test was used for categorical variables.
‡ Statistically significant value (p < 0.05).
§ The median and median absolute deviation are reported.

tionship between etiology (PTE or non-PTE) and Engel class (p < 0.0001, Cochran-Mantel-Haenszel statistic), and PTE patients were significantly more likely to attain a favorable clinical response of ≥ 50% reduced seizure frequency with an OR of 1.32 (95% CI 1.07–1.61).

Baseline seizure frequency and baseline seizure type were not used as part of the case-control matching process, but looking at these variables after the selections were made revealed that there were no significant differences between the 2 groups after matching at either 3 or 24 months (see Table 1 for seizure frequency and Fig. 4 for seizure types). As many patients presented with multiple seizure types, each seizure type was analyzed separately. The mean number of AEDs at baseline and at follow-up visits were compared for PTE versus non-PTE patients (Table 2). For the patients with 3-month data, the non-PTE group had a statistically significantly higher average number of baseline AEDs (p = 0.02), but the actual difference of 2.52 versus 2.36 AEDs would not seem to play a significant role in the observed clinical outcome at 3 months. Among the patients with 24-month data, the difference in baseline AEDs was no longer statistically significant (p = 0.77). The number of AEDs taken during the follow-up visits was lower than at baseline for both groups, but the 2 groups no longer showed any statistical difference at 3 or 24 months (p = 0.09 and p = 0.51, respectively).

Discussion

Posttraumatic epilepsy is one of the most challenging forms of epilepsy to treat because of its high rate of resistance to antiepileptic medications and our poor ability to localize epileptic foci for resection.15 Given the 500,000
patients (OR 1.32, 95% CI 1.07–1.61). This difference is important, as practitioners may rely on responder rates in determining whether to treat with VNS therapy. Overall, these findings are in line with recent observations, including those in 2 retrospective cases series and 1 meta-analysis, suggesting that PTE patients attain even greater clinical benefit from VNS therapy than patients with drug-resistant epilepsy unrelated to trauma.

What are the neurobiological mechanisms of VNS in the treatment of PTE? Previous human and animal studies have demonstrated that vagal stimulation leads to desynchronization and an overall decrease in abnormal electroencephalographic spiking patterns, which may contribute to its antiepilepticogenic effects. Recently, Smith and colleagues specifically examined neurophysiological changes induced by VNS in a fluid percussion injury model of PTE in animals. These authors observed psychomotor recovery in brain-injured rats after vagal stimulation, suggesting enhanced neural plasticity related to norepinephrine release, as well as increased survival of neurons secreting γ-aminobutyric acid. While further basic research is necessary to fully elucidate these mechanisms, it is possible that VNS triggers remodeling of the neural circuitry, including the preservation of inhibitory neurotransmission in patients with TBI, contributing to the clinical benefit in patients with PTE.

It is important to recognize the limitations of VNS therapy in PTE and other epilepsies to guide treatment discussions and manage the expectations of both patients and physicians. While many patients with epilepsy benefit from VNS, complete seizure freedom is rare, and some patients unfortunately experience no improvement in symptoms. Additionally, it is important to appreciate the often delayed clinical benefit of VNS during the first few months of its application. Previous studies have shown that VNS improves quality of life and mood in patients with epilepsy. However, other authors dispute that there is any significant quality-of-life improvement when there is anything less than complete seizure freedom. Further study on quality-of-life measures in VNS therapy is needed, but given the known debilitating effects of frequent seizures, VNS may be considered in patients with PTE who are poor candidates for resection and in whom medical therapy has failed.

Besides patients with epilepsy, those with TBI suffer from other neurological and psychological sequelae not studied in this report, including depression, anxiety disorders, neurocognitive deficits, and chronic headache. Vagus nerve stimulation has provided benefit in patients suffering from treatment-resistant depression and received FDA approval for this therapeutic purpose in 2005. Possible therapeutic effects of VNS in drug-resistant anxiety disorders and chronic headache are also being examined. Thus, the potential effects of VNS on neuropsychological profiles in patients with TBI will be important to consider going forward.

It is necessary to acknowledge significant limitations in the present study. First, registry data were derived from an industry-sponsored database and analyzed in part by...
Cyberonics, Inc., the manufacturer of the VNS therapy system. This conflict of interest raises the issue of potential bias, but it is also important to note that previous investigators have authenticated the integrity of the systems for collecting and processing the registry data by using an independent auditing agency.\textsuperscript{3} Next, given the nature of patient registries, we cannot independently ascertain the validity of clinical data submitted by individual phy-

TABLE 2: Case-control data: AEDs of PTE versus non-PTE patients*  

<table>
<thead>
<tr>
<th>Variable</th>
<th>FU Duration (mos)</th>
<th>PTE Patients</th>
<th>Non-PTE Patients</th>
<th>p Value\textsuperscript{†}</th>
</tr>
</thead>
<tbody>
<tr>
<td>baseline AEDs</td>
<td>3</td>
<td>2.36 ± 0.92</td>
<td>2.52 ± 0.89</td>
<td>0.02\textsuperscript{‡}</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>2.32 ± 1.01</td>
<td>2.36 ± 0.92</td>
<td>0.77</td>
</tr>
<tr>
<td>AEDs at FU</td>
<td>3</td>
<td>2.10 ± 1.13</td>
<td>2.26 ± 1.17</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>2.15 ± 1.12</td>
<td>2.26 ± 1.05</td>
<td>0.51</td>
</tr>
</tbody>
</table>

* The number of patients = 239 (PTE) and 478 (non-PTE) at 3 months and 59 (PTE) and 118 (non-PTE) at 24 months.

† Reflects the Student t-test to compare the means.

‡ Statistically significant value (p < 0.05).
sicians. Importantly, epilepsy etiology, as analyzed here as posttraumatic or nontraumatic, was not independently verified, and thus we are relying on the accurate reporting of the prescribing physicians. While measures were taken to enhance the reliability of our results, such as the exclusion of ambiguous epilepsy etiologies and the utilization of a case-control study design, the possibilities of reporting inaccuracy and selection bias cannot be excluded. Clearly, this uncertainty would be best addressed in a large prospective trial of VNS therapy in patients with PTE. Regardless, the strength of this evaluation lies in the ability to pool a very large number of cases, which would be difficult to achieve even in a multiinstitutional trial.

Conclusions

There is a great need for improved treatment strategies for PTE, as it is one of the most challenging forms of epilepsy to manage. Vagus nerve stimulation is an adjuvantive treatment for patients with medically refractory epilepsy who are not good candidates for definitive resection. Utilizing a case-control study design to analyze seizure outcomes from a large, prospectively collected patient registry, we found that patients with PTE may achieve better outcomes after VNS therapy than individuals with nontraumatic epilepsy etiologies. Overall, 78% of patients with PTE responded favorably to VNS therapy (that is, ≥ 50% reduction in seizure frequency) after 24 months of treatment, compared with only 61% of patients with non-PTE (OR 1.32, 95% CI 1.07–1.61). These data suggest that VNS may be considered in patients with medically refractory PTE who are not favorable candidates for resection. A controlled prospective study is necessary to validate these observations.

Disclosure

Two authors (K.H.H. and C.M.G.) are employees of Cyberonics, Inc., the manufacturer of the VNS Therapy System and sponsor of the VNS Therapy Patient Outcome Registry. They assisted in the statistical analyses.

Acquisition of data: Gordon. Analysis and interpretation of data: Englot, Rolston, Wang, Chang. Drafting the article: Englot. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Englot. Statistical analysis: Englot, Hassnain, Gordon. Study supervision: Chang.

References

26. McLachlan RS, Rose KJ, Derry PA, Bonnar C, Blume WT,
Vagus nerve stimulation for posttraumatic epilepsy


Please include this information when citing this paper: published online September 14, 2012; DOI: 10.3171/2012.8.JNS12.8.

Address correspondence to: Dario J. Englot, M.D., Ph.D., Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, Box 0112, San Francisco, California 94143-0112. email: EnglotDJ@neurosurg.ucsf.edu.